NVX CoV2705 / Novavax - LARVOL DELTA

Safety and Immunogenicity of NVX-CoV2705 (clinicaltrialsregister.eu) - P3 | N=660 | Sponsor: Sanofi Vaccines US Inc.

New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Comparative Effectiveness of mRNA-1273 Versus Protein-Based NVX-CoV2705 Vaccination on COVID-19-Related Outcomes Among Insured Adults in the United States During 2024-2025: A Retrospective Matched Cohort Study. (PubMed, Adv Ther) - "In this insured US adult population, mRNA-1273 demonstrated greater effectiveness against medically attended COVID-19 and hospitalization with COVID-19 than the protein-based NVX-CoV2705. These findings highlight the potential public-health importance of considering vaccine platform and variant selection when planning for upcoming seasons."

HEOR • Journal • Retrospective data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and Immunogenicity of NVX-CoV2705 (clinicaltrials.gov) - P3 | N=676 | Completed | Sponsor: Sanofi | Active, not recruiting ➔ Completed | Trial primary completion date: Apr 2026 ➔ Jan 2026

Trial completion • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19: Efficacy and Safety of NVX-CoV2705 (clinicaltrials.gov) - P4 | N=6500 | Active, not recruiting | Sponsor: Novavax | Not yet recruiting ➔ Active, not recruiting | Trial completion date: Jul 2026 ➔ Dec 2026 | Trial primary completion date: Jan 2026 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Reactogenicity (clinicaltrials.gov) - P4 | N=1000 | Active, not recruiting | Sponsor: Marcel Curlin | Trial completion date: Jun 2028 ➔ Jun 2026 | Trial primary completion date: Apr 2027 ➔ Jun 2026 | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Trial completion date • Trial primary completion date • Infectious Disease • Novel Coronavirus Disease

Safety and Immunogenicity of NVX-CoV2705 (clinicaltrials.gov) - P3 | N=676 | Active, not recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Active, not recruiting | N=120 ➔ 676

Enrollment change • Enrollment closed • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

Safety and immunogenicity of a single dose of a JN.1 variant COVID-19 vaccine in previously vaccinated adults: Primary analysis report of a phase 3 open-label trial. (PubMed, Vaccine) - P3 | "A single dose of NVX-CoV2705 induced a rapid and robust anti-SARS-CoV-2 immune response against the Omicron JN.1 and other circulating variants and had an acceptable safety profile. https://clinicaltrials.gov/study/NCT06409663."

Journal • P3 data • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19: Efficacy and Safety of NVX-CoV2705 (clinicaltrials.gov) - P4 | N=6500 | Not yet recruiting | Sponsor: Novavax

New P4 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

A Strain Change Study for SARS-CoV-2 rS Vaccines (clinicaltrials.gov) - P3 | N=60 | Completed | Sponsor: Novavax | Active, not recruiting ➔ Completed

Trial completion • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19: Safety and Immunogenicity of NVX-CoV2705 (clinicaltrials.gov) - P3 | N=120 | Not yet recruiting | Sponsor: Novavax

New P3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19 Reactogenicity (clinicaltrials.gov) - P4 | N=1000 | Not yet recruiting | Sponsor: Marcel Curlin

New P4 trial • Infectious Disease • Novel Coronavirus Disease

A Strain Change Study for SARS-CoV-2 rS Vaccines (clinicaltrials.gov) - P3 | N=60 | Active, not recruiting | Sponsor: Novavax | Not yet recruiting ➔ Active, not recruiting | Phase classification: P2/3 ➔ P3 | N=100 ➔ 60 | Trial completion date: Feb 2025 ➔ Jun 2025

Enrollment change • Enrollment closed • Phase classification • Trial completion date • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases

COVID-19: Phase 3 Strain Change Study for SARS-CoV-2 rS Vaccines (clinicaltrials.gov) - P2/3 | N=100 | Not yet recruiting | Sponsor: Novavax

New P2/3 trial • Infectious Disease • Novel Coronavirus Disease • Respiratory Diseases